Latest News



Ario Pharma Commences Phase IIa Trial of TRPV1 Inhibitor for Cough associated with Chronic Obstructive Pulmonary Disease.

Cambridge, UK, 11 February 2014. Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and...


2-Year MIMICS Data Confirm Long-term Patency Protection With BioMimics 3D.

6 February 2014 – Seroba Kernel's investee company, Veryan Medical Ltd, presented two-year follow-up data at the annual Leipzig Interventional Course (LINC) today. The two-year data has shown that a nitinol stent with unique three-dimensional helical geometry, BioMimics 3D™, developed by Veryan Medical Ltd, (Horsham, UK) provides an improvement in long-term patency compared...


< back to home page